Capital Guardian Trust’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Capital Guardian Trust’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-186	Closed	-$2K	–	802
2016 Q1	$2K	Buy	+186	New	+$2K	﹤0.01%	766

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Guardian Trust's MNTA Position: Q2 2016 in Review

Capital Guardian Trust sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2016, closing a stake of 186 shares — an estimated $2K sold.

Capital Guardian Trust first reported a position in MNTA in Q1 2016 and held it in 1 quarter. The position peaked at $2K in Q1 2016. 146 funds tracked by Wall St. Rank hold MNTA as of Q2 2016.

Capital Guardian Trust reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Capital Guardian Trust sold 186 Momenta Pharmaceuticals, Inc. shares in Q2 2016, an estimated $2K.
Capital Guardian Trust first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
Capital Guardian Trust's Momenta Pharmaceuticals, Inc. position peaked at $2K in Q1 2016.
146 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2016.

Based on Capital Guardian Trust's 13F filing for Q2 2016, filed 15 Aug 2016.